You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
|
|---|---|
| Published in |
Journal of Experimental & Clinical Cancer Research, December 2014
|
| DOI | 10.1186/s13046-014-0102-9 |
| Pubmed ID | |
| Authors |
Rouzbeh Daylami, Diego J Muilenburg, Subbulakshmi Virudachalam, Richard J Bold |
| Abstract |
BackgroundPancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy (gemcitabine) and enter the clinical treatment arena.MethodsWe examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2, hENT1, and dCK) were examined.ResultsCombination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor of RRM2.ConclusionThe ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great promise in the treatment of advanced pancreatic cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 31% |
| Student > Bachelor | 4 | 15% |
| Other | 2 | 8% |
| Student > Master | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 5 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 38% |
| Biochemistry, Genetics and Molecular Biology | 5 | 19% |
| Agricultural and Biological Sciences | 2 | 8% |
| Nursing and Health Professions | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 6 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2014.
All research outputs
#22,759,802
of 25,374,647 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,967
of 2,378 outputs
Outputs of similar age
#310,421
of 363,226 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#15
of 22 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,378 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 363,226 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.